Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 30;403(10433):1279-1289.
doi: 10.1016/S0140-6736(23)02843-X. Epub 2024 Mar 13.

Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort

Collaborators, Affiliations

Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort

Katie Wong et al. Lancet. .

Erratum in

  • Department of Error.
    [No authors listed] [No authors listed] Lancet. 2025 Apr 5;405(10485):1146. doi: 10.1016/S0140-6736(25)00622-1. Lancet. 2025. PMID: 40187841 No abstract available.

Abstract

Background: Individuals with rare kidney diseases account for 5-10% of people with chronic kidney disease, but constitute more than 25% of patients receiving kidney replacement therapy. The National Registry of Rare Kidney Diseases (RaDaR) gathers longitudinal data from patients with these conditions, which we used to study disease progression and outcomes of death and kidney failure.

Methods: People aged 0-96 years living with 28 types of rare kidney diseases were recruited from 108 UK renal care facilities. The primary outcomes were cumulative incidence of mortality and kidney failure in individuals with rare kidney diseases, which were calculated and compared with that of unselected patients with chronic kidney disease. Cumulative incidence and Kaplan-Meier survival estimates were calculated for the following outcomes: median age at kidney failure; median age at death; time from start of dialysis to death; and time from diagnosis to estimated glomerular filtration rate (eGFR) thresholds, allowing calculation of time from last eGFR of 75 mL/min per 1·73 m2 or more to first eGFR of less than 30 mL/min per 1·73 m2 (the therapeutic trial window).

Findings: Between Jan 18, 2010, and July 25, 2022, 27 285 participants were recruited to RaDaR. Median follow-up time from diagnosis was 9·6 years (IQR 5·9-16·7). RaDaR participants had significantly higher 5-year cumulative incidence of kidney failure than 2·81 million UK patients with all-cause chronic kidney disease (28% vs 1%; p<0·0001), but better survival rates (standardised mortality ratio 0·42 [95% CI 0·32-0·52]; p<0·0001). Median age at kidney failure, median age at death, time from start of dialysis to death, time from diagnosis to eGFR thresholds, and therapeutic trial window all varied substantially between rare diseases.

Interpretation: Patients with rare kidney diseases differ from the general population of individuals with chronic kidney disease: they have higher 5-year rates of kidney failure but higher survival than other patients with chronic kidney disease stages 3-5, and so are over-represented in the cohort of patients requiring kidney replacement therapy. Addressing unmet therapeutic need for patients with rare kidney diseases could have a large beneficial effect on long-term kidney replacement therapy demand.

Funding: RaDaR is funded by the Medical Research Council, Kidney Research UK, Kidney Care UK, and the Polycystic Kidney Disease Charity.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests ERM reports support for the current manuscript from VHL UK/Ireland and consulting fees from MSD. SM is chair of OxalEurope. MS reports support for the current manuscript from a Medical Research Council UK Precision Medicine programme grant (MR/R013942/1) and consulting fees from Travere Therapeutics. RJC reports support for the current manuscript from Kidney Research UK. JAS reports support for the current manuscript from Kidney Research UK, Northern Counties Kidney Research Fund, and the Medical Research Council UK (all payments to institution). JAS is Academic Vice President of the UK Kidney Association. FWKT reports support from the National Institute for Health and Care Research Imperial Biomedical Centre. DN is the UK Kidney Association Director of Informatics Research. DPG reports support for the current manuscript from St Peter's Trust for Kidney Bladder and Prostate Research, Medical Research Council, Kidney Research UK, Kidney Care UK, and Polycystic Kidney Disease Charity (all payments to institution). DPG chairs the Rare Diseases Committee of the UK Kidney Association and reports fees for consulting and presenting from Novartis, Alexion, Calliditas, Sanofi, Britannia, and Travere. All other authors declare no competing interests.

Figures

Figure 1
Figure 1
Kaplan-Meier estimates of cumulative incidence of kidney failure for glomerular (A) and cystic kidney diseases (B) Data for all diseases are shown in the appendix (p 4). Data are censored for death. ADPKD=autosomal dominant polycystic kidney disease. ADTKD=autosomal dominant tubulointerstitial kidney disease. ANCA=antineutrophil cytoplasmic antibody. eGFR=estimated glomerular filtration rate. MPGN–C3G=membranoproliferative glomerulonephritis and C3 glomerulopathy. SRNS–FSGS=steroid resistant nephrotic syndrome, congenital nephrotic syndrome, or focal segmental glomerulosclerosis. SSNS–MCD=steroid sensitive nephrotic syndrome or minimal change disease.
Figure 2
Figure 2
Kaplan-Meier estimates of median time from diagnosis to eGFR value for glomerular (A) and cystic kidney diseases (B) Data for all diseases are shown in the appendix (p 8). ADPKD=autosomal dominant polycystic kidney disease. ADTKD=autosomal dominant tubulointerstitial kidney disease. ANCA=antineutrophil cytoplasmic antibody. eGFR=estimated glomerular filtration rate. GBM=glomerular basement membrane. MPGN–C3G=membranoproliferative glomerulonephritis and C3 glomerulopathy. SRNS–FSGS=steroid resistant nephrotic syndrome, congenital nephrotic syndrome, or focal segmental glomerulosclerosis. SSNS–MCD=steroid sensitive nephrotic syndrome or minimal change disease.
Figure 3
Figure 3
Observed vs predicted kidney failure within 2 years in RaDaR patients Patients with eGFR >15 and <60 mL/min per 1·73 m2 at recruitment who remained alive with more than 2 years of follow-up data are shown. Observed kidney failure exceeded that predicted by the KFRE (Hosmer-Lemeshow test; p<0·0001). Data stratified by age group are shown in the appendix (p 12). Blue dashed line indicates observed proportion of kidney failure within 2 years equalling the predicted risk score. KFRE=kidney failure risk equation. RaDaR=the National Registry of Rare Kidney Diseases.

Comment in

References

    1. UK Government CKD prevalence estimates for local and regional populations. 2015. https://www.gov.uk/government/publications/ckd-prevalence-estimates-for-...
    1. Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet. 2017;389:1238–1252. - PubMed
    1. Thomas S, Caplan A. The orphan drug act revisited. JAMA. 2019;321:833–834. - PubMed
    1. Moliner AM, Waligora J. The European Union Policy in the field of rare diseases. Adv Exp Med Biol. 2017;1031:561–587. - PubMed
    1. Devuyst O, Knoers NVAM, Remuzzi G, Schaefer F. Rare inherited kidney diseases: challenges, opportunities, and perspectives. Lancet. 2014;383:1844–1859. - PMC - PubMed

Publication types

MeSH terms